Abcam, ab308394, Anti-Respiratory Syncytial virus Nucleoprotein antibody [HL1246]

Size: 100µL
Rabbit Recombinant Monoclonal NCAP antibody. Carrier free. Suitable for ICC/IF, WB and reacts with Transfected cell line, Transfected cell line - Respiratory syncytial virus samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:HL1246,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Respiratory syncytial virus,
Applications:ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.

Product details:
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Respiratory Syncytial Virus Nucleoprotein (RSV N protein) plays a central mechanical role in the replication and transcription of the RSV genome. It binds single-stranded RNA acting as a scaffold for the virus's RNA synthesis. The nucleocapsid protein another name for RSV N protein has a molecular mass of approximately 45 kilodaltons. It is expressed in cells infected by the RSV notably within the cytoplasm forming a protective helix around the viral RNA genome.
Biological function summary
Within the context of viral infection and replication RSV N protein is essential for packaging and protecting the viral RNA genome. It forms part of a complex with the phosphoprotein (P protein) and the large polymerase protein (L protein) to facilitate RNA replication and transcription. This complex ensures the stability and integrity of the viral genome allowing the virus to efficiently replicate and produce infectious particles. Therefore the nucleoprotein strongly influences the life cycle of the virus.
Pathways
The RSV N protein functional capacity is pivotal within the viral RNA transcription and replication pathways. It closely interacts with the phosphoprotein P enhancing the activity of the viral RNA-dependent RNA polymerase complex. This interaction synergistically ties into the virus's replication pathway ensuring the production of viral RNAs. The N protein also coordinates with M2-1 protein in regulating mRNA synthesis and RNA processing reflecting its comprehensive involvement in essential viral pathways.
The involvement of RSV N protein connects strongly to respiratory tract infections particularly in infants and the elderly. RSV infection often leads to bronchiolitis and pneumonia where the N protein plays an important role in propagating the disease. Its interaction with the fusion glycoprotein (F protein) facilitates virus assembly and release which enhances viral spread and subsequent infection severity. Researchers often focus on these proteins when developing therapeutics targeting RSV-related diseases.